AstraZeneca PLC
LSE:AZN

Watchlist Manager
AstraZeneca PLC Logo
AstraZeneca PLC
LSE:AZN
Watchlist
Price: 10 018 GBX 3.63% Market Closed
Market Cap: 155.3B GBX
Financials Section:
Income Statement Balance Sheet Cash Flow Statement
|
Revenue Breakdown

Revenue Breakdown

Breakdown by Geography
AstraZeneca PLC

Total Revenue: 54.1B USD
100%
The Americas: 20.8B USD
38.4%
Asia, Africa And Australasia: 11.9B USD
22.1%
Europe: 9.7B USD
18%
China: 5.9B USD
10.9%
Japan: 3.6B USD
6.7%
Uk: 3.4B USD
6.2%
Other, Europe: 3.1B USD
5.8%
Sweden: 1.7B USD
3.2%
France: 1.2B USD
2.1%
Canada: 967m USD
1.8%
Spain: 847m USD
1.6%
Italy: 813m USD
1.5%
Australia: 390m USD
0.7%
Show More

Breakdown by Segments
AstraZeneca PLC

Total Revenue: 54.1B USD
100%
Total Oncology: 17.1B USD
31.7%
Cvrm: 10.6B USD
19.6%
Rare Disease: 7.8B USD
14.4%
Farxiga: 6B USD
11%
Tagrisso: 5.8B USD
10.7%
Imfinzi: 4.2B USD
7.8%
Soliris: 3.1B USD
5.8%
Ultomiris: 3B USD
5.5%
Lynparza: 2.8B USD
5.2%
Calquence: 2.5B USD
4.6%
Symbicort: 2.4B USD
4.4%
Fasenra: 1.6B USD
2.9%
Brilinta: 1.3B USD
2.4%
Total Other Medicines: 1.2B USD
2.2%
Strensiq: 1.2B USD
2.1%
Crestor: 1.1B USD
2%
Enhertu: 1B USD
1.9%
Zoladex: 952m USD
1.8%
Nexium: 945m USD
1.7%
Pulmicort: 713m USD
1.3%
Breztri: 677m USD
1.3%
Seloken/Toprol-Xl: 640m USD
1.2%
Synagis: 546m USD
1%
Lokelma: 412m USD
0.8%
Koselugo: 331m USD
0.6%
Faslodex: 297m USD
0.5%
Saphnelo: 280m USD
0.5%
Roxadustat: 271m USD
0.5%
Other, Others: 231m USD
0.4%
Onglyza: 227m USD
0.4%
Oncology, Others: 224m USD
0.4%
Flumist: 216m USD
0.4%
Andexxa: 182m USD
0.3%
Kanuma: 171m USD
0.3%
Bydureon: 163m USD
0.3%
Bevespi: 58m USD
0.1%
Daliresp/Daxas: 54m USD
0.1%
Vaxzevria: 12m USD
0%
Show More

See Also

Summary
AZN intrinsic value, competitors valuation, and company profile.
DCF Valuation
AZN stock valuation using Discount Cash Flow valuation method.
Relative Valuation
AZN stock valuation using valuation multiples.
Wall Street Estimates
AZN price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
AZN stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Follow us
Join more than 245,500+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.